Reviewing Homology Medicines Inc. (FIXX)’s and Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS)’s results

Both Homology Medicines Inc. (NASDAQ:FIXX) and Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS) are each other’s competitor in the Biotechnology industry. Thus the contrast of their risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Homology Medicines Inc. 2.83M 282.31 70.85M -1.52 0.00
Sunesis Pharmaceuticals Inc. N/A 0.00 25.20M -0.75 0.00

In table 1 we can see Homology Medicines Inc. and Sunesis Pharmaceuticals Inc.’s top-line revenue, earnings per share and valuation.


Table 2 hightlights the return on assets, net margins and return on equity of the two companies.

Net Margins Return on Equity Return on Assets
Homology Medicines Inc. -2,503.53% -39.1% -24.7%
Sunesis Pharmaceuticals Inc. 0.00% 235.2% -123.9%


Homology Medicines Inc.’s Current Ratio is 8.7 while its Quick Ratio is 8.7. On the competitive side is, Sunesis Pharmaceuticals Inc. which has a 1.3 Current Ratio and a 1.3 Quick Ratio. Homology Medicines Inc. is better positioned to pay off short and long-term obligations compared to Sunesis Pharmaceuticals Inc.

Analyst Recommendations

In next table is delivered Homology Medicines Inc. and Sunesis Pharmaceuticals Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Homology Medicines Inc. 0 0 1 3.00
Sunesis Pharmaceuticals Inc. 0 1 1 2.50

Homology Medicines Inc.’s consensus price target is $36, while its potential upside is 94.07%. Competitively the consensus price target of Sunesis Pharmaceuticals Inc. is $3.25, which is potential 261.11% upside. The results provided earlier shows that Sunesis Pharmaceuticals Inc. appears more favorable than Homology Medicines Inc., based on analyst view.

Institutional and Insider Ownership

Roughly 81.2% of Homology Medicines Inc. shares are owned by institutional investors while 50.1% of Sunesis Pharmaceuticals Inc. are owned by institutional investors. 8.76% are Homology Medicines Inc.’s share owned by insiders. Competitively, insiders own roughly 0.2% of Sunesis Pharmaceuticals Inc.’s shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Homology Medicines Inc. 1.53% 0.4% -6.56% 11.82% 15.9% 0.72%
Sunesis Pharmaceuticals Inc. -15.38% -10.37% 128.3% -12.95% -54.34% 191.08%

For the past year Homology Medicines Inc. has weaker performance than Sunesis Pharmaceuticals Inc.


Sunesis Pharmaceuticals Inc. beats Homology Medicines Inc. on 6 of the 11 factors.

Homology Medicines, Inc., a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, via a single intravenous injection, a range of disease-relevant tissues, including the liver, central nervous system, bone marrow, lung, muscle and eye, across modalities?gene editing and gene therapy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company is developing vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). It has completed a Phase III, randomized, double-blind, and placebo-controlled trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AML. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome; and developing SNS-062, a non-covalently binding inhibitor of the human protein BrutonÂ’s tyrosine kinase (BTK). The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.